Harborside


MediPharm Labs Corp.

TSE: LABS


Canadian symbol: LABS.TO
US symbol: MEDIF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 26.07M
Enterprise Value -2.05M
Trailing P/E 187.00
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)1.18
Price/Book (mrq)0.34
Enterprise Value/Revenue -0.10
Enterprise Value/EBITDA 0.05

Trading Information

Stock Price History

Beta (5Y Monthly) 0.95
52-Week Change 3-73.91%
S&P500 52-Week Change 3-3.39%
52 Week High 30.3700
52 Week Low 30.0600
50-Day Moving Average 30.0758
200-Day Moving Average 30.1491

Share Statistics

Avg Vol (3 month) 3408.1k
Avg Vol (10 day) 3380.37k
Shares Outstanding 5274.38M
Implied Shares Outstanding 6N/A
Float 8251.59M
% Held by Insiders 14.00%
% Held by Institutions 17.41%
Shares Short (Jul 28, 2022) 46.75M
Short Ratio (Jul 28, 2022) 417.26
Short % of Float (Jul 28, 2022) 4N/A
Short % of Shares Outstanding (Jul 28, 2022) 42.46%
Shares Short (prior month Jun 29, 2022) 47.21M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2021
Most Recent Quarter (mrq)Mar 30, 2022

Profitability

Profit Margin -229.42%
Operating Margin (ttm)-219.31%

Management Effectiveness

Return on Assets (ttm)-26.06%
Return on Equity (ttm)-49.65%

Income Statement

Revenue (ttm)21.09M
Revenue Per Share (ttm)0.08
Quarterly Revenue Growth (yoy)-11.20%
Gross Profit (ttm)-13.42M
EBITDA -41.08M
Net Income Avi to Common (ttm)-48.39M
Diluted EPS (ttm)-0.1840
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)28.27M
Total Cash Per Share (mrq)0.1
Total Debt (mrq)156k
Total Debt/Equity (mrq)0.20
Current Ratio (mrq)7.19
Book Value Per Share (mrq)0.28

Cash Flow Statement

Operating Cash Flow (ttm)-12.84M
Levered Free Cash Flow (ttm)793.25k

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
LABS.TO
MediPharm Labs
1 day ago
LABS.TO
MediPharm Labs
2 weeks ago
LABS.TO
MediPharm Labs
1 month ago
LABS.TO
MediPharm Labs
3 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
4 months ago
LABS.TO
MediPharm Labs
5 months ago
LABS.TO
MediPharm Labs
5 months ago
LABS.TO
MediPharm Labs
7 months ago
LABS.TO
MediPharm Labs
7 months ago
LABS.TO
MediPharm Labs
7 months ago
LABS.TO
MediPharm Labs
8 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
9 months ago
LABS.TO
MediPharm Labs
11 months ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
1 year ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
2 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago
LABS.TO
MediPharm Labs
3 years ago

Currency in CAD
Earnings EstimateCurrent Qtr. (Jun 2022)Next Qtr. (Sep 2022)Current Year (2022)Next Year (2023)
No. of Analysts2243
Avg. Estimate-0.02-0.02-0.08-0.05
Low Estimate-0.02-0.02-0.1-0.06
High Estimate-0.02-0.02-0.06-0.05
Year Ago EPS-0.05-0.03-0.22-0.08
Revenue EstimateCurrent Qtr. (Jun 2022)Next Qtr. (Sep 2022)Current Year (2022)Next Year (2023)
No. of Analysts3343
Avg. Estimate5.4M5.97M24.16M29.68M
Low Estimate5M5M21M24M
High Estimate5.61M6.5M27.31M33.05M
Year Ago Sales6.76MN/A21.71M24.16M
Sales Growth (year/est)-20.10%N/A11.30%22.80%
Earnings History2021-06-292021-09-292021-12-302022-03-30
EPS Est.-0.03-0.02-0.02-0.02
EPS Actual-0.05-0.03-0.08-0.03
Difference-0.02-0.01-0.06-0.01
Surprise %-66.70%-50.00%-300.00%-50.00%
EPS TrendCurrent Qtr. (Jun 2022)Next Qtr. (Sep 2022)Current Year (2022)Next Year (2023)
Current Estimate-0.02-0.02-0.08-0.05
7 Days Ago-0.02-0.02-0.08-0.05
30 Days Ago-0.02-0.02-0.08-0.05
60 Days Ago-0.02-0.02-0.08-0.05
90 Days Ago-0.02-0.01-0.07-0.05
EPS RevisionsCurrent Qtr. (Jun 2022)Next Qtr. (Sep 2022)Current Year (2022)Next Year (2023)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesLABS.TOIndustrySector(s)S&P 500
Current Qtr.60.00%N/AN/AN/A
Next Qtr.33.30%N/AN/AN/A
Current Year63.60%N/AN/AN/A
Next Year37.50%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in CAD
Breakdown
4.00%% of Shares Held by All Insider
7.41%% of Shares Held by Institutions
7.72%% of Float Held by Institutions
4Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Captrust Financial Advisors1,850Mar 30, 20220.00%157

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
ETF Managers Tr-EFTMG Alternative Harvest ETF17,527,835Mar 30, 20226.34%1,489,865
Spinnaker ETF Tr-Cannabis ETF6,701,704May 30, 20222.42%569,644
Amplify Seymour Cannabis ETF2,844,844Apr 29, 20221.03%241,811
Cambria ETF Tr-Cambria Cannabis ETF616,080Jun 29, 20220.22%52,366
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by MediPharm Labs Corp.


MediPharm Labs Sets Date to Report Second Quarter 2022 Financial Results

MediPharm Labs Sets Date to Report Second Quarter 2022 Financial Results

BARRIE, ON, Aug. 11, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release second quarter financial results for the three and six month period ended June 30, 2022 before markets open on Monday, August 15, ... Read More...
MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

MediPharm Labs Enters Cannabis Research Agreement with Keck School of Medicine of USC

MediPharm to design, manufacture and supply a liquid oral cannabis study drug for the Phase 2 Life's end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) study, to be conducted in the U.S., across 20 sites. The lead investigators have been awarded a total of US$16M grant from the US National Institutes of Health and the National ... Read More...
MediPharm Labs Awarded Payment of $9.8M in Connection to a 2020 Statement of Claim Against a Previous Customer

MediPharm Labs Awarded Payment of $9.8M in Connection to a 2020 Statement of Claim Against a Previous Customer

BARRIE, ON, July 27, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced that it has been awarded a favourable summary of judgement in the Ontario Court of Justice in connection with a supply agreement disput... Read More...
MediPharm Labs Enters into $6.2M Purchase Agreement for the Sale of Australian Facility

MediPharm Labs Enters into $6.2M Purchase Agreement for the Sale of Australian Facility

BARRIE, ON, July 11, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, has entered into a Share Purchase Agreement (the "Agreement") with OneLife Botanicals PTY ("OneLife Botanicals") for the sale of MediPharm Labs Australia Pty Ltd ("... Read More...
MediPharm Labs Announces Voting Results From the 2022 Annual Meeting of Shareholders

MediPharm Labs Announces Voting Results From the 2022 Annual Meeting of Shareholders

BARRIE, ON, June 30, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced the results of matters voted on at its annual meeting of holders of common shares held on Thursday, June 30, 2022 (the "Meeting"). The voting result... Read More...
MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results

MediPharm Labs Sets Date to Report First Quarter 2022 Financial Results

TORONTO, May 12, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three month period ended March 31, 2022 before markets open on Monday, May 16, 2022. MediPhar... Read More...
MediPharm Labs Names Experienced Pharma and Med Tech Executive David Pidduck, as CEO

MediPharm Labs Names Experienced Pharma and Med Tech Executive David Pidduck, as CEO

BARRIE, ON, April 20, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs", "MediPharm") a pharmaceutical company specializing in precision-based cannabinoids, today announced that it has appointed experienced Pharma and Med Tech executive David Pidduck as Chief Executive Officer and Director of the Company.... Read More...
MediPharm Labs Reports Fourth Quarter and Full Year 2021 Results

MediPharm Labs Reports Fourth Quarter and Full Year 2021 Results

TORONTO, March 31, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the three and twelve months ended December 31, 2021. 2021 – Select Operating Highlights Expanded internation... Read More...
MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2021 Financial Results

MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2021 Financial Results

TORONTO, March 29, 2022 - MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release fourth quarter financial results for the three and twelve month period ended December 31, 2021 after markets close on Thursday, Marc... Read More...
MediPharm Labs Strengthens Recreational Business Adding Flower and Pre-Rolls to Portfolio

MediPharm Labs Strengthens Recreational Business Adding Flower and Pre-Rolls to Portfolio

Known for its high-quality, specialty recreational dried flower products, Shelter Cannabis is expected to complement MediPharm's existing Canadian cannabis portfolio. Adds IP and well-regarded Shelter brands Wildlife and Shelter Craft to MediPharm. MediPharm expects to leverage its recently expanded national sales network to drive Shelte... Read More...
MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

Completed a Drug Master File ("DMF") process for CBD Active Pharmaceutical Ingredient ("API") for the US Federal Drug Administration ("FDA"). Use of Canadian Drug Establishment Licence ("DEL") to register API with the FDA for commercial opportunities in pharmaceutical development, novel drugs and generic drugs. The cannabis-based drug ... Read More...
MediPharm Labs Provides Operational Update and Confirms Profitability Improvement Initiatives are Underway

MediPharm Labs Provides Operational Update and Confirms Profitability Improvement Initiatives are Underway

Strong cash balance and continued reduction of convertible debt to less than $500K.Opportunities for optimization of the operating strategy between Australia and Canada as the Canadian Drug Establishment Licence (DEL) unlocks many manufacturing and supply chain pathways. These pathways will reduce infrastructure cost, improve delivery tim... Read More...
MediPharm Labs Announces Changes to Board of Directors

MediPharm Labs Announces Changes to Board of Directors

BARRIE, Ontario, Dec. 07, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce changes to its Board of Directors (the “Board”). Effectively immediately, Pat McCutcheon, Warren Everitt and Keith Str... Read More...
MediPharm Reports Third Quarter 2021 Results; Announces New CEO to Start Today

MediPharm Reports Third Quarter 2021 Results; Announces New CEO to Start Today

BARRIE, Ontario, Nov. 15, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids today announced its financial results for the three and nine months ended September 30, 2021, a period of transition in establishing itself as an i... Read More...
MediPharm Labs Completes a New Cannabis Oil Delivery to German Partner Vayamed

MediPharm Labs Completes a New Cannabis Oil Delivery to German Partner Vayamed

New strategic partnership through the delivery of GMP extract to Germany for Vayamed, the medical cannabis business unit of Sanity GroupVayamed is a well-established operating medical cannabis company in Germany, where the medical cannabis market is expected to be worth €7.7 billion by 2028 according to Forbes BARRIE, Ontario, Oct. 19, 20... Read More...
Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

Insomnia Treatment Study using MediPharm Labs CBD50 Product to Proceed to Phase 2 with Health Canada Consent

McMaster University researchers using MediPharm Labs’ CBD50 formula and a CBD:THC 10:2 formulation, which has the same cannabinoid ratio as MediPharm Labs’ CBD25:, have received a No Objection Letter from Health Canada to begin recruiting human subjects for a placebo-controlled trial using cannabis- oil for treatment of insomnia in major ... Read More...
MediPharm Labs Australia Receives Government Grant to Assist with International Expansion

MediPharm Labs Australia Receives Government Grant to Assist with International Expansion

Received first instalment of a government grant for $330,000AUD as part of the Australian government’s Manufacturing Modernisation program aimed at supporting manufacturers scaling their businesses.Grant to be used for automation of downstream manufacturing and scaling purification abilities.Government grant as part of broader manufacturi... Read More...
MediPharm Labs Receives Export Authorization to Ship Medical Cannabis to Brazil

MediPharm Labs Receives Export Authorization to Ship Medical Cannabis to Brazil

Completed the regulatory process required to ship medical cannabis to Brazil with import permits issued from ANVISA and export permits issued from Health Canada. Initial deliveries will be under the compassionate care program.First shipments to Brazil to be used for patient trials to collect data that may be used in future product marketi... Read More...
MediPharm Reports Second Quarter 2021 Results and Advances Pharmaceutical Strategy; Announces new Board Chair

MediPharm Reports Second Quarter 2021 Results and Advances Pharmaceutical Strategy; Announces new Board Chair

BARRIE, Ontario, Aug. 16, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished dose products today announced its financial results for the three and six months ended June 30, 2021,... Read More...
MediPharm Labs Achieves Major Pharmaceutical Manufacturing Milestone: Receives Canadian GMP Pharmaceutical Drug Establishment Licence

MediPharm Labs Achieves Major Pharmaceutical Manufacturing Milestone: Receives Canadian GMP Pharmaceutical Drug Establishment Licence

Health Canada Drug Establishment Licence allows MediPharm Labs to conduct pharmaceutical manufacturing and sale of Active Pharmaceutical Ingredients and Pharmaceutical Drug ProductsMakes MediPharm Labs a full-service pharmaceutical company that can support the global pharma entry into the drugs containing cannabis market, including in the... Read More...
MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates

MediPharm Labs Enters Research Agreement with McMaster University to Develop Drugs Containing Cannabis Candidates

MediPharm Labs’ Cannabis Drug Licence and expertise qualifies and positions the Company to supply clinical trial material, assist in investigation protocol and provide regulatory support for multiple trialsThree initial proposed clinical trials will evaluate the effectiveness of proprietary THC and CBD drug candidates for multiple indicat... Read More...
MediPharm Labs Announces Voting Results From the 2021 Annual Meeting of Shareholders

MediPharm Labs Announces Voting Results From the 2021 Annual Meeting of Shareholders

BARRIE, Ontario, June 10, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the results of matters voted on at its annual meeting of holders ... Read More...
MediPharm Labs Extends Strategic Partnership with ADREXpharma and continues to Build its Presence in Germany

MediPharm Labs Extends Strategic Partnership with ADREXpharma and continues to Build its Presence in Germany

MediPharm and ADREXpharma continue to lead the way addressing rising patient demand in the burgeoning German Medical Cannabis Market that saw sales increase 34% last year 128,000 active patients at end of 2020; German patients spent an average of $500EUR per month, finished products and extract sales continue to gain market share MediPhar... Read More...
MediPharm Labs Launches High-CBD Wellness Oils in Quebec; Ships First Order of CBD 25 and CBD 50 Formulas Now Available for Retail Sale by SQDC

MediPharm Labs Launches High-CBD Wellness Oils in Quebec; Ships First Order of CBD 25 and CBD 50 Formulas Now Available for Retail Sale by SQDC

BARRIE, Ontario, May 26, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced it launched its first wellness products in Quebec and shipped its ... Read More...
MediPharm Reports First Quarter 2021 Results, Provides Strategic Update

MediPharm Reports First Quarter 2021 Results, Provides Strategic Update

BARRIE, Ontario, May 17, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation and derivative products today announced its financial results for the three months ended March 31, 2021, a period of ongoing progress i... Read More...
MediPharm Labs Sets Date to Report First Quarter 2021 Financial Results

MediPharm Labs Sets Date to Report First Quarter 2021 Financial Results

TORONTO, May 11, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release first quarter financial results for the three month ... Read More...
MediPharm Labs Expands Global Portfolio in 9 Countries Including Medical and Wellness Customers for Turnkey Manufacturing and Distribution Solutions; New Supply Deal Reached With MT Pharma in Malta

MediPharm Labs Expands Global Portfolio in 9 Countries Including Medical and Wellness Customers for Turnkey Manufacturing and Distribution Solutions; New Supply Deal Reached With MT Pharma in Malta

BARRIE, Ontario, April 26, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced through its wholly owned subsidiary, it has signed a new agreeme... Read More...
MediPharm Labs Completes Its First High THC Cannabis Oil Export to Peru

MediPharm Labs Completes Its First High THC Cannabis Oil Export to Peru

MediPharm Labs’ high THC medical cannabis has been successfully exported to Peru for distribution by specialized compounding pharmaciesPeru marks MediPharm Labs’ first Latin American export following successful exports to Australia and Germany BARRIE, Ontario, April 08, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“... Read More...
MediPharm Labs Achieves Export Milestone, Ships Cannabis Oil from Australia to Germany

MediPharm Labs Achieves Export Milestone, Ships Cannabis Oil from Australia to Germany

MediPharm Labs exports commercial shipment of medical cannabis products approved by the Australian Therapeutic Goods Administration (TGA) to patients in GermanyAn export milestone for the Australian cannabis industry as an export hubGermany is one of the most heavily regulated export markets in the world, this export milestone strengthens... Read More...
European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement

European Pharmaceutical Company STADA and MediPharm Labs Begin First Sales in Germany Under Exclusive Agreement

BARRIE, Ontario, April 01, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced STADA Arzneimittel AG (STADA), a leading European consumer health and generics co... Read More...
MediPharm Labs Reports Fourth Quarter and Full Year 2020 Results

MediPharm Labs Reports Fourth Quarter and Full Year 2020 Results

BARRIE, Ontario, March 31, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation and derivative products today announced its financial results for the three and twelve months ended December 31, 2020. “We are e... Read More...
MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2020 Financial Results

MediPharm Labs Sets Date to Report Fourth Quarter and Full Year 2020 Financial Results

TORONTO, March 29, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, is pleased to announce it will release fourth quarter financial results for the three and... Read More...
MediPharm Labs Expands Wellness Portfolio, Launches Next Generation of Oils with New Unique CBN Rich Formula

MediPharm Labs Expands Wellness Portfolio, Launches Next Generation of Oils with New Unique CBN Rich Formula

BARRIE, Ontario, March 26, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced a further expansion of its innovative, pharma-quality family of ... Read More...
MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

MediPharm Labs Expands Distribution Revenue Footprint in Canada, Enters Growing Quebec Market Through New Supply Agreement

Quebec marks the Company’s 7th provincial distribution supply agreementMediPharm Labs expanded distribution footprint represents potential coverage of an estimated 95%+ of retail market in CanadaMediPharm Labs will be selling its MediPharm Labs and LABS Cannabis product lines in QuebecTORONTO, March 09, 2021 -- MediPharm Labs Corp. (TSX: ... Read More...
MediPharm Labs Australia Signs Supply and Manufacturing Agreement with Cannim Australia; Announces Plan to Launch New Over-the-Counter Products

MediPharm Labs Australia Signs Supply and Manufacturing Agreement with Cannim Australia; Announces Plan to Launch New Over-the-Counter Products

TORONTO, March 08, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, is pleased to announce its wholly owned subsidiary, MediPharm Labs Australia Pty Ltd (“MediPharm Labs Australi... Read More...
MediPharm Labs Closes Previously Announced Bought Deal Equity Financing

MediPharm Labs Closes Previously Announced Bought Deal Equity Financing

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, March 05, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative pr... Read More...
MediPharm Labs Announces Increase to Bought Deal Equity Financing to $29 Million

MediPharm Labs Announces Increase to Bought Deal Equity Financing to $29 Million

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESTORONTO, March 02, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative pr... Read More...
MediPharm Labs Receives Milestone Cannabis Drug Licence to Manufacture and Distribute Pharmaceuticals Containing Cannabis Including New Drugs for Discovery Trials

MediPharm Labs Receives Milestone Cannabis Drug Licence to Manufacture and Distribute Pharmaceuticals Containing Cannabis Including New Drugs for Discovery Trials

TORONTO, Feb. 17, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, announced it has received a Cannabis Drug Licence (“CDL licence”) from Health Canada.The CDL licence is a criti... Read More...
MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors

MediPharm Labs Appoints Warren Everitt, CEO Australia Pacific, to Board of Directors

TORONTO, Jan. 15, 2021 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality cannabis extraction, distillation and derivative products, today announced the appointment of Warren Everitt to its Board of Directors (the “Board”),... Read More...
MediPharm Labs Announces Leadership Changes

MediPharm Labs Announces Leadership Changes

BARRIE, Ontario, Dec. 10, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a global leader in specialized, research-driven cannabis extraction, distillation and derivative products, today announced a senior leadership transition.To prepare the Company for its next phase of growth and ... Read More...
MediPharm Labs Reports Third Quarter 2020 Results

MediPharm Labs Reports Third Quarter 2020 Results

BARRIE, Ontario, Nov. 16, 2020 -- MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven cannabis extraction, distillation and derivative products today announced its financial results for the three and nine months ended September 30, 2020 and outlined... Read More...
Coming Soon.
IndexLast% Change
S&P 5004,302.14

0.12%Positive

Euro STOXX 503,805.22

0.41%Positive

FTSE 1007,536.06

0.36%Positive

Nikkei 22528,868.91

0.01%Negative


Delayed data (1h)
IndexLast% Change
S&P 5004,302.14

0.12%Positive

Euro STOXX 503,805.22

0.41%Positive

FTSE 1007,536.06

0.36%Positive

Nikkei 22528,868.91

0.01%Negative



Share this page